ESR1 mutation detection for breast cancer diagnosis

The AmoyDx® Super-ARMS ESR1 PCR Kit provides a high level of sensitivity and precision in detecting 29 mutations in the ESR1 gene across exons 4, 5, 6, 7 and 8, in circulating free DNA (cfDNA). This is especially beneficial for identifying patients who may respond to targeted therapies, enabling earlier, more informed treatment decisions. The kit offers a cost-effective solution by reducing the need for more expensive alternatives, such as whole genome sequencing, while still delivering highly accurate results. It is designed to be easy to automate, integrating seamlessly into existing workflows, increasing throughput, and reducing labour costs.

Benefits of the AmoyDx® Super-ARMS ESR1 PCR kit

• Fast turnaround: delivers results from plasma sample to report in under 5.5 hours.
• Comprehensive mutation coverage: includes 29 ESR1 mutations across multiple exons for detailed analysis.
• Efficient process: quick DNA extraction (10 minutes) and automated data analysis for seamless workflow.
• Flexible instrument compatibility: works with QuantStudio5 and SLAN-96S instruments for versatile use.
• User-friendly kit format: each kit contains 14 tests, simplifying the preparation process.
• Long shelf life: the kit remains stable for 12 months, ensuring reliable use.
• Research-focused: specifically designed for research use, ideal for mutation studies in breast cancer.

Applications of the AmoyDx® Super-ARMS ESR1 PCR kit

• ESR1 mutation detection: identifying ESR1 mutations in breast cancer for treatment planning.
• Personalised medicine: tailoring breast cancer therapies based on specific genetic mutations.
• cfDNA analysis: detecting mutations from cell-free DNA (cfDNA) extracted from plasma samples.
• Research on breast cancer: studying the role of ESR1 mutations in cancer progression and therapy resistance.
• Clinical research: evaluating the effectiveness of targeted therapies for patients with ESR1 mutations.
• Biomarker validation: validating ESR1 mutations as biomarkers for monitoring breast cancer treatments.
• Genetic screening: screening for ESR1 mutations in patient cohorts for clinical studies

Specifications

Materials for download

AmoyDx® Super-ARMS ESR1 PCR Kit brochure